The Pharma Letter4d
Bristol Myers’ Phase III Opdualag trial misses goal
Bristol Myers Squibb today announced the Phase III RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) ...
Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
FiercePharma4d
Bristol Myers Squibb comes up short in bid to expand Opdualag in melanoma
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatl ...
pharmaphorum4d
BMS study of Opdualag in adjuvant melanoma ends in failure
Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab ...
MedCity News5d
Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma
A Bristol Myers Squibb immunotherapy currently approved ... Participants were dosed with the study drug, Opdualag, in combination with Nivolumab, a different BMS immunotherapy that’s already ...
BioSpace4d
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as ...
Bristol-Myers' Opdualag fails Phase 3 melanoma study
Bristol-Myers Squibb (NYSE:BMY) said that the Phase 3 RELATIVITY-098 study of its drug Opdualag in the treatment of late-stage melanoma didn't meet its primary endpoint. The drugmaker had been testing ...